Clinical Trial Detail

NCT ID NCT01810016
Title NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Ludwig Institute for Cancer Research
Indications

melanoma

Therapies

Ipilimumab

NY-ESO-1 peptide vaccine

Age Groups: adult

No variant requirements are available.